Gilead Sciences (GILD) : Rockland Trust Co scooped up 3,756 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 20, 2016. The investment management firm now holds a total of 142,107 shares of Gilead Sciences which is valued at $12,299,361.Gilead Sciences makes up approximately 2.03% of Rockland Trust Co’s portfolio.
Other Hedge Funds, Including , Fcm Investmentstx reduced its stake in GILD by selling 2,231 shares or 3.58% in the most recent quarter. The Hedge Fund company now holds 60,157 shares of GILD which is valued at $5,206,588. Gilead Sciences makes up approx 3.00% of Fcm Investmentstx’s portfolio.Tnb Financial boosted its stake in GILD in the latest quarter, The investment management firm added 3,624 additional shares and now holds a total of 60,929 shares of Gilead Sciences which is valued at $5,280,107. Gilead Sciences makes up approx 1.35% of Tnb Financial’s portfolio.Hall Laurie J Trustee boosted its stake in GILD in the latest quarter, The investment management firm added 420 additional shares and now holds a total of 950 shares of Gilead Sciences which is valued at $81,463. Gilead Sciences makes up approx 0.05% of Hall Laurie J Trustee’s portfolio.Forte Capital Adv boosted its stake in GILD in the latest quarter, The investment management firm added 151 additional shares and now holds a total of 49,778 shares of Gilead Sciences which is valued at $4,268,464. Gilead Sciences makes up approx 1.61% of Forte Capital Adv’s portfolio.Gulf International Bank (uk) Ltd reduced its stake in GILD by selling 23,857 shares or 5.48% in the most recent quarter. The Hedge Fund company now holds 411,100 shares of GILD which is valued at $35,251,825. Gilead Sciences makes up approx 0.58% of Gulf International Bank (uk) Ltd’s portfolio.
Gilead Sciences opened for trading at $85.46 and hit $87.12 on the upside on Wednesday, eventually ending the session at $86.66, with a gain of 1.43% or 1.22 points. The heightened volatility saw the trading volume jump to 90,55,877 shares. Company has a market cap of $115,416 M.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Gabelli & Co Initiated Gilead Sciences on Jun 1, 2016 to “Buy”, Price Target of the shares are set at $109.Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.